Antimetabolite

Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman, and Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin will participate in the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.

Key Points: 
  • In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions.
  • A live video webcast of the Event will be available on the Events page of the Investors section of the Company's website ( moleculin.com ).
  • The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
Thursday, September 8, 2022

Details of the presentations are as follows:

Key Points: 
  • Details of the presentations are as follows:
    Title: The Value of Collaboration in Clinical Development: Experience from Poland
    For more information about the conference, visit: www.roswellpark.org/msc-symposium .
  • is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses.
  • The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022

HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Key Points: 
  • HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .
  • The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

Retrieved on: 
Tuesday, September 6, 2022

HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").

Key Points: 
  • HOUSTON, Sept. 6, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation of WP1122 for the treatment of Glioblastoma Multiforme ("GBM").
  • "The receipt of Orphan Drug Designation represents an important milestone for our promising WP1122 development program," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.
  • Based on preclinical data indicating the potential for WP1122 as a treatment for GBM, Moleculin received Investigational New Drug status and is evaluating opportunities for collaboration in clinical development.
  • The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States.

Global Cytotoxic Drugs Market Estimated to Reach $14,885.2 Million by 2028 and Grow at 1.2% CAGR in the 2021-2028 Timeframe [202-Pages] | Report by Research Dive

Retrieved on: 
Monday, June 13, 2022

NEW YORK, June 13, 2022 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Cytotoxic Drugs Market by Drug Type (Alkylating Agents, Antitumor Antibiotics, Antimetabolites, Plant Alkaloids, and Other Drug Types), Route of Administration (Parenteral and Oral), Application (Breast Cancer, Prostate Cancer, Lung Cancer, Pancreatic Cancer, and Other Applications), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021–2028".

Key Points: 
  • - The global cytotoxic drugs market is expected to grow by 2028 due to the increasing prevalence of cancer.
  • According to the report, the global cytotoxic drugs market is expected to gather a revenue of $14,885.2 million by 2028, growing at a CAGR of 1.2% during the 2021-2028 timeframe.
  • Restraints: Low penetration of the cytotoxic drugs, especially in low-income countries, may hamper the growth trajectory of the cytotoxic drugs market.
  • By drug type, the antimetabolites drugs sub-segment of the cytotoxic drugs market is estimated to have a dominating share and garner $6,908.1 million by 2028.

Moleculin to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 19, 2022

HOUSTON, May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Key Points: 
  • HOUSTON, May 19, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information, please visit the conference website .
  • For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Retrieved on: 
Wednesday, May 4, 2022

HOUSTON, May 4, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Company has engaged Wolfram C. M. Dempke, MD, PhD, MBA, MRCP as its EU Chief Medical Officer and part-time contractor for its European clinical trials.  

Key Points: 
  • Dr. Dempke continues to teach classes in the Munich University Medical Oncology department, Germany, and he even continues to see patients on a monthly basis.
  • Walter Klemp, President and Chief Executive Officer of Moleculin commented, "As we look to commence our clinical studies in Europe, we believe Dr. Dempke will be a tremendous asset.
  • We are honored and pleased to have his leadership and guidance for our European clinical teams and help to drive these important programs forward."
  • Additionally he served as the Executive Medical Director and Global Clinical Lead (Global Medical Oncology) at AstraZeneca.

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

Retrieved on: 
Thursday, April 21, 2022

HOUSTON, April 21, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma.

Key Points: 
  • With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma.
  • "WP1066 has demonstrated significant anti-tumor activity in a wide range of tumor cell lines and increased survival in a number of animal models to-date.
  • WP1066 is currently being evaluated in collaboration with Emory University for the treatment of pediatric brain tumors, including Diffuse Interstitial Pontine Glioma (DIPG).
  • Forward-looking statements in this release include, without limitation, Moleculin's ability to secure a strategic partnership or collaboration to conduct a Phase 1 trial.

Moleculin Announces Corporate Rebranding and Launch of New Website

Retrieved on: 
Thursday, April 14, 2022

HOUSTON, April 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the launch its new corporate branding and website www.moleculin.com.

Key Points: 
  • HOUSTON, April 14, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the launch its new corporate branding and website www.moleculin.com .
  • We are wholeheartedly committed to potentially solving some of the toughest challenges and importantly, bringing better treatments to patients where there remains unmet medical need.
  • I am excited for this evolution of Moleculin and to take another step forward towards the future of this exciting company," commented Walter Klemp, Chairman and CEO of Moleculin.
  • The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Retrieved on: 
Wednesday, March 23, 2022

HOUSTON, March 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chairman and CEO of Moleculin Biotech, will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.

Key Points: 
  • HOUSTON, March 23, 2022 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chairman and CEO of Moleculin Biotech, will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.
  • As part of the conference, a video webcast of the Company's presentation will be available for viewing on-demand for those who are registered to attend.
  • The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.
  • For more information about the Company, please visit www.moleculin.com and connect on Twitter , LinkedIn and Facebook .